Navigation Links
Dyadic International Raises $3 Million in Private Placement of Convertible Notes
Date:10/5/2011

JUPITER, Fla., Oct. 5, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced that it has completed a private placement of $3,000,000 in convertible subordinated secured promissory notes (the "Notes") to five investors.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

The Notes will pay interest quarterly at a rate of 8% per annum and are convertible at the holder's option into shares of Dyadic common stock.  Unless converted, the Notes will mature on January 1, 2013.

Dyadic expects to use proceeds from this offering for working capital including continued investments in research and development, new product introductions and general corporate purposes.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dyadic International Reports 2011 Second Quarter Financial Results
2. Dyadic International Announces Date of Second Quarter 2011 Financial Results Release and Conference Call
3. Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry
4. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
5. Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio
6. New U.S. Patent Issued to Dyadic International
7. Dyadic International to Present at Advanced Biofuels Leadership Conference
8. Dyadic International Introduces Advanced Biofuels Enzyme AlternaFuel® CMAX™ At World Biofuels Markets
9. Dyadic International Reports 2010 Fiscal Year Financial Results
10. Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
11. Dyadic International Reports 2010 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
Breaking Biology News(10 mins):